Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 7/20 | 0.77 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18362030 | 0.88 | LOXL2 (0.59) | LOXL2MAP2K7HTR6SIGMAR1 | |
| SCHEMBL19952936 | 0.88 | LOXL2 (0.98) | LOXL2MAP2K7MEN1KMT2ASIGMAR1 | |
| Hydrochloric Acid SCHEMBL20337945 | 0.87 | LOXL2 (1.00) | LOXL2MAP2K7MEN1KMT2ASIGMAR1 | |
| SCHEMBL18361801 | 0.86 | LOXL2 (0.70) | LOXL2THRB | |
| SCHEMBL18362116 | 0.83 | LOXL2 (0.54) | LOXL2HTR6SIGMAR1 | |
| SCHEMBL20337892 | 0.81 | LOXL2 (0.62) | LOXL2MAP2K7SIGMAR1 | |
| SCHEMBL20337855 | 0.77 | LOXL2 (0.58) | LOXL2HTR6SIGMAR1 | |
| SCHEMBL18361800 | 0.77 | LOXL2 (0.57) | LOXL2MEN1KMT2ACYP1A2THRB | |
| SCHEMBL18362005 | 0.76 | LOXL2 (0.77) | LOXL2MEN1KMT2ACYP1A2 | |
| SCHEMBL18362024 | 0.76 | LOXL2 (0.56) | LOXL2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017003862-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. (US) | 2017-01-05 | — | — | WO | disclosed |